Skip to Content

We invite you to try out our new beta eCFR site at We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page!


Controlled Substances: Proposed Adjustment to the Aggregate Production Quotas for 2012

This document was corrected by a document published on 07/11/2012. View Correction

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Drug Enforcement Administration (DEA), Department of Justice.


Notice with request for comments.


This notice proposes to adjust the 2012 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act (CSA).


Electronic comments must be submitted and written comments must be postmarked on or before August 6, 2012. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period.


To ensure proper handling of comments, please reference “Docket No. DEA-363” on all electronic and written correspondence. DEA encourages all comments be submitted electronically through using the electronic comment form provided on that site. An electronic copy of this document is also available at the Web site for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to will be posted for public review and are part of the official docket record. Should you, however, wish to submit written comments via regular or express mail, they should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152.

Start Further Info


John W. Partridge, Chief, Liaison and Policy Section, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 307-4654.

End Further Info End Preamble Start Supplemental Information


Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at and in the DEA's public docket. Such information includes personal identifying Start Printed Page 39738information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in the DEA's public docket file. Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the FOR FURTHER INFORMATION CONTACT paragraph.


Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. The 2012 established aggregate production quotas for controlled substances in schedules I and II were published in the Federal Register (76 FR 78044) on December 15, 2011. That notice stipulated that, as provided for in 21 CFR 1303.13, all aggregate production quotas are subject to adjustment.

Analysis for Proposed Revised 2012 Aggregate Production Quotas

DEA now proposes to adjust the established 2012 aggregate production quotas for some schedule I and II controlled substances. In proposing the adjustment, DEA has taken into account the criteria that DEA is required to consider in accordance with 21 CFR 1303.13. DEA proposes the adjustment of the aggregate production quotas for basic classes of schedule I and II controlled substances by considering (1) Changes in demand for the class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national and/or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand can be met through existing inventories, increased individual manufacturing quotas, or increased importation without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Administrator finds relevant.

In determining whether to propose adjustments to the 2012 aggregate production quotas, DEA considered updated information obtained from 2011 year-end inventories, 2011 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to DEA after the initial aggregate production quotas had been established. The Deputy Administrator, therefore, proposes to adjust the 2012 aggregate production quotas for some schedule I and II controlled substances, expressed in grams of anhydrous acid or base, as follows:

Basic classPreviously established 2012 quotasProposed adjusted 2012 quotas
Schedule I
1-[1-(2-Thienyl)cyclohexyl]piperidine0 g5 g.
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)45 gNo Change.
1-Butyl-3-(1-naphthoyl)indole (JWH-073)45 gNo Change.
1-Methyl-4-phenyl-4-propionoxypiperidine2 gNo Change.
1-Pentyl-3-(1-naphthoyl)indole (JWH-018)45 gNo Change.
2,5-Dimethoxyamphetamine2 g12 g.
2,5-Dimethoxy-4-ethylamphetamine (DOET)2 g12 g.
2,5-Dimethoxy-4-n-propylthiophenethylamine2 g12 g.
3-Methylfentanyl2 gNo Change.
3-Methylthiofentanyl2 gNo Change.
3,4-Methylenedioxyamphetamine (MDA)22 g30 g.
3,4-Methylenedioxy-N-methylcathinone (methylone)8 g12 g.
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)15 g24 g.
3,4-Methylenedioxymethamphetamine (MDMA)22 g30 g.
3,4-Methylenedioxypyrovalerone (MDPV)8 g12 g.
3,4,5-Trimethoxyamphetamine2 g12 g.
4-Bromo-2,5-dimethoxyamphetamine (DOB)2 g12 g.
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)2 g12 g.
4-Methoxyamphetamine77 g88 g.
4-Methylaminorex2 g12 g.
4-Methyl-2,5-dimethoxyamphetamine (DOM)2 g12 g.
4-Methyl-N-methylcathinone (mephedrone)8 g12 g.
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol68 gNo Change.
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol53 gNo Change.
Start Printed Page 39739
5-Methoxy-3,4-methylenedioxyamphetamine2 g12 g.
5-Methoxy-N,N-diisopropyltryptamine2 g12 g.
Acetyl-alpha-methylfentanyl2 gNo Change.
Acetyldihydrocodeine2 gNo Change.
Acetylmethadol2 gNo Change.
Allylprodine2 gNo Change.
Alphacetylmethadol2 gNo Change.
Alpha-ethyltryptamine2 g12 g.
Alphameprodine2 gNo Change.
Alphamethadol2 gNo Change.
Alpha-methylfentanyl2 gNo Change.
Alpha-methylthiofentanyl2 gNo Change.
Alpha-methyltryptamine (AMT)2 g12 g.
Aminorex2 g12 g.
Benzylmorphine2 gNo Change.
Betacetylmethadol2 gNo Change.
Beta-hydroxy-3-methylfentanyl2 gNo Change.
Beta-hydroxyfentanyl2 gNo Change.
Betameprodine2 gNo Change.
Betamethadol2 gNo Change.
Betaprodine2 gNo Change.
Bufotenine3 gNo Change.
Cathinone4 g12 g.
Codeine-N-oxide602 gNo Change.
Diethyltryptamine2 g12 g.
Difenoxin50 gNo Change.
Dihydromorphine3,608,000 gNo Change.
Dimethyltryptamine7 g18 g.
Gamma-hydroxybutyric acid47,000,000 gNo Change.
Heroin20 gNo Change.
Hydromorphinol54 gNo Change.
Hydroxypethidine2 gNo Change.
Ibogaine5 gNo Change.
Lysergic acid diethylamide (LSD)16 gNo Change.
Marihuana21,000 gNo Change.
Mescaline5 g13 g.
Methaqualone10 gNo Change.
Methcathinone4 g12 g.
Methyldihydromorphine2 gNo Change.
Morphine-N-oxide655 gNo Change.
N-Benzylpiperazine2 g12 g.
N,N-Dimethylamphetamine2 g12 g.
N-Ethylamphetamine2 g12 g.
N-Hydroxy-3,4-methylenedioxyamphetamine2 g12 g.
Noracymethadol2 gNo Change.
Norlevorphanol52 gNo Change.
Normethadone2 gNo Change.
Normorphine18 gNo Change.
Para-fluorofentanyl2 gNo Change.
Phenomorphan2 gNo Change.
Pholcodine2 gNo Change.
Properidine2 gNo Change.
Psilocybin2 gNo Change.
Psilocyn2 gNo Change.
Tetrahydrocannabinols393,000 gNo Change.
Thiofentanyl2 gNo Change.
Tilidine10 gNo Change.
Trimeperidine2 gNo Change.
Schedule II
1-Phenylcyclohexylamine2 gNo Change.
1-Piperdinocyclohexanecarbonitrile2 g27 g.
4-Anilino-N-phenethyl-4-piperidine (ANPP)1,800,000 gNo Change.
Alfentanil15,000 g19,550 g.
Alphaprodine2 gNo Change.
Amobarbital40,007 gNo Change.
Amphetamine (for conversion)8,500,000 g
Amphetamine (for sale) *25,300,000 g33,400,000 g.
Start Printed Page 39740
* DEA has determined that the revised total quantity to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stock is 29,400,000 g. DEA has further determined that an additional 4,000,000 g is necessary to provide for future research and development needs and unexpected emergencies that could affect market availability.
Carfentanil0 g5 g.
Cocaine216,000 gNo Change.
Codeine (for conversion)65,000,000 gNo Change.
Codeine (for sale)39,605,000 gNo Change.
Dextropropoxyphene7 gNo Change.
Dihydrocodeine400,000 gNo Change.
Diphenoxylate900,000 gNo Change.
Ecgonine83,000 gNo Change.
Ethylmorphine2 gNo Change.
Fentanyl1,428,000 gNo Change.
Glutethimide2 gNo Change.
Hydrocodone (for sale)59,000,000 g63,000,000 g.
Hydromorphone3,455,000 g3,628,000 g.
Isomethadone4 gNo Change.
Levo-alphacetylmethadol (LAAM)3 gNo Change.
Levomethorphan5 gNo Change.
Levorphanol3,600 gNo Change.
Lisdexamfetamine12,000,000 gNo Change.
Meperidine5,500,000 gNo Change.
Meperidine Intermediate-A5 gNo Change.
Meperidine Intermediate-B9 gNo Change.
Meperidine Intermediate-C5 gNo Change.
Metazocine5 gNo Change.
Methadone (for sale)20,000,000 gNo Change.
Methadone Intermediate26,000,000 gNo Change.
Methamphetamine3,130,000 gNo Change.
[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)]
Methylphenidate56,000,000 gNo Change.
Morphine (for conversion)83,000,000 gNo Change.
Morphine (for sale)39,000,000 gNo Change.
Nabilone20,502 gNo Change.
Noroxymorphone (for conversion)7,200,000 gNo Change.
Noroxymorphone (for sale)401,000 g1,981,000 g.
Opium (powder)63,000 g73,000 g.
Opium (tincture)1,000,000 gNo Change.
Oripavine9,800,000 g15,300,000 g.
Oxycodone (for conversion)5,600,000 gNo Change.
Oxycodone (for sale)98,000,000 g98,700,000 g.
Oxymorphone (for conversion)12,800,000 gNo Change.
Oxymorphone (for sale)5,500,000 gNo Change.
Pentobarbital34,000,000 gNo Change.
Phenazocine5 gNo Change.
Phencyclidine24 gNo Change.
Phenmetrazine2 gNo Change.
Phenylacetone16,000,000 gNo Change.
Racemethorphan2 gNo Change.
Remifentanil2,500 gNo Change.
Secobarbital336,002 gNo Change.
Sufentanil5,000 gNo Change.
Tapentadol5,400,000 gNo Change.
Thebaine116,000,000 gNo Change.

Aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR part 1303, the Deputy Administrator may adjust the 2012 aggregate production quotas and individual manufacturing quotas allocated for the year.


Pursuant to 21 CFR 1303.11 and 1303.13, any interested person may submit written comments on or objections to these proposed determinations. Based on comments received in response to this Notice, the Deputy Administrator may hold a public hearing on one or more issues raised. In the event the Deputy Administrator decides in his sole discretion to hold such a hearing, the Deputy Administrator will publish a notice of any such hearing in the Federal Register. After consideration of any comments and after a hearing, if one is held, the Deputy Administrator will publish in the Federal Register a Final Start Printed Page 39741Order determining any adjustment of the aggregate production quota.

Start Signature

Dated: June 28, 2012.

Michele M. Leonhart,


End Signature End Supplemental Information

[FR Doc. 2012-16396 Filed 7-3-12; 8:45 am]